Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

German pharmaceutical giant Merck has completed a €3 billion ($3.5 billion) takeover of US biopharmaceutical company Springworks Therapeutics, the firm confirmed on Tuesday. With the acquisition, ...

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has completed its $3.9 billion acquisition of Stamford-based SpringWorks ...

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.